Retreating to steroid-sparing claims can preserve a drug facing withdrawal for data manipulation.
When unblinding and database tampering strip a rare disease drug of its primary superiority claims, developers can avoid complete market erasure by proving the therapy still spares patients from glucocorticoid toxicity.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Amgen launched an independent trial re-evaluation to salvage a drug facing regulatory withdrawal following a high-profile journal retraction for data manipulation.
Amgen is seeking to protect Tavneos from withdrawal by leveraging clinical data that highlights its steroid-sparing therapeutic value.
Faced with the loss of its clinical superiority claim over data manipulation allegations, Amgen pivoted its regulatory defense to focus entirely on the drug's steroid-sparing benefit.